Tekin Aksu

Tekin Aksu

Auto-generated profile, based on publicly available information

Tekin Aksu

Department of Pediatric Hematology and Oncology Hacettepe University Faculty of Medicine Ankara Türkiye

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2023 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
TATekin Aksu
Tekin Aksu
ŞÜŞule Ünal
Şule Ünal
Iron deficiency is the most common nutrient deficiency in the world. Epidemiological data indi- cate that iron deficiency is more prevalent in infants, in preschool-children, and in adolescents. Etiologies of iron deficiency in children include inadequate dietary iron intake, which is the most common cause, as well as increased iron requirements, bleeding, and intestinal iron absorption disorders. Iron deficiency can lead to symptoms related to anemia, may interfere with neuro- development and may cause skin, hair, nail, and gastrointestinal problems. This review focuses on the causes, signs, symptoms, diagnosis and management of iron deficiency in infancy, child- hood, and adolescence. Cite this article as: Aksu T, Ünal Ş. Iron deficiency anemia in infancy, childhood, and adolescence. Turk Arch Pediatr. 2023;58(4):358-362.

9 July 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
HTHemanth Tummala
Hemanth Tummala
ADArran D. Dokal
Arran D. Dokal
AWAmanda Walne
Amanda Walne
AEAlicia Ellison
Alicia Ellison
SCShirleny Cardoso
Shirleny Cardoso
TVTom Vulliamy
Tom Vulliamy
Significance: Bone marrow failure (BMF) is an inherited life-threatening condition characterized by defective hematopoiesis, developmental abnormalities, and predisposition to cancer. BMF caused by ERCC6L2 mutations is considered to be a genome instability syndrome, because DNA repair is compromised in patient cells. In this study, we report BMF cases with biallelic disease-causing variants and provide evidence from patients’ cells that transcription deficiency can explain the genome instability. Specifically, we demonstrate that ERCC6L2 participates in RNA polymerase II-mediated transcription via interaction with DNA-dependent protein kinase (DNA-PK) and resolves DNA–RNA hybrids (R loops). Collectively, our data point to a causal mechanism in BMF in which patients with ERCC6L2 mutations are defective in the repair of transcription-associated DNA damage.

20 September 2018 in Blood
Verified
Journal Article
Open access
PDF file
HTHemanth Tummala
Hemanth Tummala
LCLaura C. Collopy
Laura C. Collopy
AWAmanda J. Walne
Amanda J. Walne
AEAlicia Ellison
Alicia Ellison
SCShirleny Cardoso
Shirleny Cardoso
IDInderjeet Dokal
Inderjeet Dokal

12 January 2021
Verified
Journal Article
Closed access
SBShahrzad Bakhtiar
Shahrzad Bakhtiar
ESEmilia Salzmann-Manrique
Emilia Salzmann-Manrique
HBHenric-Jan Blok
Henric-Jan Blok
DEDirk-Jan Eikema
Dirk-Jan Eikema
SHSheree Hazelaar
Sheree Hazelaar
ALArjan Lankester
Arjan Lankester
Type I and III leukocyte adhesion deficiencies (LADs) are primary immunodeficiency disorders resulting in early death due to infections and additional bleeding tendency in LAD-III. The curative treatment of LAD-I and LAD-III is allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this retrospective multicenter study, data were collected using the European Society for Blood and Marrow Transplantation registry; we analyzed data from 84 LAD patients from 33 centers, all receiving an allo-HSCT from 2007 to 2017. The 3-year overall survival estimate (95% confidence interval [CI]) was 83% (74-92) for the entire cohort: 84% (75-94) and 75% (50-100) for LAD-I and LAD-III, respectively. We observed cumulative incidences (95% CI) of graft failure (GF) at 3 years of 17% (9%-26%) and grade II to IV acute graft-versus-host disease (aGVHD) at 100 days of 24% (15%-34%). The estimate (95% CI) at 3 years for GF- and GVHD-II to IV-free survival as event-free survival (EFS) was 56% (46-69) for the entire cohort; 58% (46-72) and 56% (23-88) for LAD-I and LAD-III, respectively. Grade II to IV acute GVHD was a relevant risk factor for death (hazard ratio 3.6; 95% CI 1.4-9.1; P = .006). Patients' age at transplant >= 13 months, transplantation from a nonsibling donor, and any serological cytomegalovirus mismatch in donor-recipient pairs were significantly associated with severe acute GVHD and inferior EFS. The choice of busulfan- or treosulfan-based conditioning, type of GVHD prophylaxis, and serotherapy did not impact overall survival, EFS, or aGVHD. An intrinsic inflammatory component of LAD may contribute to inflammatory complications during allo-HSCT, thus providing the rationale for considering anti-inflammatory therapy pretreatment.

24 September 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
TATekin Aksu
Tekin Aksu
FGFatma Gümrük
Fatma Gümrük
TBTuran Bayhan
Turan Bayhan
ÇCÇağrı Coşkun
Çağrı Coşkun
KOKader K. Oğuz
Kader K. Oğuz
SUSule Unal
Sule Unal

26 November 2008 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
SBSevcan A. Bakkaloglu
Sevcan A. Bakkaloglu
TATekin Aksu
Tekin Aksu
BGBerna Goker
Berna Goker
AAAysel Ünlüsoy Aksu
Aysel Ünlüsoy Aksu
HPHarun Peru
Harun Peru
NBNecla Buyan
Necla Buyan